

Form PTO-1449 (modified)

Atty. Docket No.

Serial N .

GOUD:031US

10/611,803

List of Patents and Publications for Applicant's

Applicant

Éric Gervais *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

July 1, 2003

Unknown

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
PA	C1	Anke <i>et al.</i> , "Questions about drugs: how do pregnant women solve them?" <i>Pharm. World Sci.</i> , 26(6):254-259, 1994.
	C2	Czeizel and Dudas, "Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation," <i>New England J. Med.</i> , 327:1832-1835, 1992.
	C3	Einarson <i>et al.</i> , "Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling," <i>J. Psychiatry Neurosci.</i> , 26(1):44-48, 2001.
	C4	Koren and Pastuszak, "Prevention of unnecessary pregnancy terminations by counseling women on drug, chemical and radiation exposure during the first trimester," <i>Teratology</i> , 41(6):657-661, 1990.
	C5	Matsui, "Drug compliance in pediatrics. Clinical and research issues," <i>Ped. Clin. N. Amer.</i> , 44(1):1-14, 1997.
	C6	Mazzotta <i>et al.</i> , "Factors associated with elective termination of pregnancy among Canadian and American women with nausea and vomiting of pregnancy," <i>J. Psychosom Obstet. Gynecol.</i> , 22(1):7-12, 2001.
	C7	Olesen <i>et al.</i> , "Do pregnant women report use of dispensed medications?" <i>Epidemiology</i> , 12(5):497-501, 2001.
PA	C8	Pastuszak <i>et al.</i> , "The effectiveness of preconceptional counseling on women's compliance with folic acid supplementation, maternal-fetal toxicology, A clinician's guide," 3 rd Edition, pp. 141-149, 2001.

25323587.1

EXAMINER:

DATE CONSIDERED:

6-8 2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

GOUD:031US

Serial No.

10/611,803

Applicant

Éric Gervais *et al.*

Filing Date:

July 1, 2003

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>pt</i>	C9	Pole <i>et al.</i> , "Drug labeling and risk perceptions of teratogenicity: A survey of pregnant Canadian women and their health professionals," <i>J. Clin. Pharmacol.</i> , 40:573-577, 2000.

25323587.1

EXAMINER: *[Signature]*DATE CONSIDERED: *6-6-2003*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket N .
GOUD:031USSerial No.
10/611,803

List of Patents and Publications for Applicant's

Applicant
Eric Gervais *et al.*



INFORMATION DISCLOSURE STATEMENT

Filing Date:
July 1, 2003Group:
1615



(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,778,984	12/06/88	Marsik	128	738	1/30/87
	A2	5,443,288	8/22/95	Miles	283	2	7/25/94
	A3	5,457,895	10/17/95	Thompson <i>et al.</i>	34	296	10/01/93
	A4	5,531,230	7/02/96	Bell	128	842	7/14/95
	A5	5,836,890	11/17/98	Jackson	600	551	5/30/97
	A6	6,223,559	5/01/01	Coleman	63	1.13	7/20/99
	A7	6,226,564	5/01/01	Stuart	700	231	11/01/96
	A8	6,340,695	1/22/02	Gervais	514	345	6/21/01

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	2,050,054	3/20/92	Canada			
	B2	2,078,578	2/05/02	Canada			
	B3	2,081,679	5/28/93	Canada			
	B4	2,280,279	2/14/00	Canada			
	B5	2,310,069	6/03/99	Canada			
	B6	2,321,991	9/02/99	Canada			
	B7	EP 1 149 572	10/31/01	Europe			
	B8	WO 2004/004694	1/15/04	PCT			
	B9	WO 97/48384	12/24/97	PCT			

25384711.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
GOUD:031USSerial No.
10/611,803

List of Patents and Publications for Applicant's

Applicant
Éric Gervais *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
July 1, 2003Group:
1615U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>R</i>	C10	Bishai <i>et al.</i> , "The efficacy and safety of Diclectin (R) (doxylamine/pyridoxine) for nausea and vomiting of pregnancy," <i>Today's Therapeutic Trends</i> , 17(2):167-179, 1999.
<i>R</i>	C11	Muno, "Broadening utility of tablet and capsule imprints," <i>Journal of Pharmacy Practice</i> , 13(2):130-140, 2000.
<i>R</i>	C12	Pedersen, "Tablet tooling: design, maintenance and troubleshooting," <i>Pharmaceutical Technology Europe</i> , 11(2):22-28, 1999.

25384711.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (Rev.7-80)	U.S. Department of Commerce Patent & Trademark Office	ATTY. DOCKET NO. AAML/11621.35	SERIAL NO. 10/611,803
LIST OF REFERENCES CITED BY APPLICANT (Use separate sheets if necessary)		APPLICANT GERVAIS, Éric et al	
		FILING DATE July 1, 2003	GROUP 1615

U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
<i>AS</i>	6,352,713	3/5/02	KIRSCHNER ET AL.	424	441	12/1/99

FOREIGN PATENT DOCUMENTS

		Document number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

		ORIFER. F., Prenatal Vitamin Supplement, Hoechst Marion Roussel, September 25, 1996.

Examiner: <i>[Signature]</i>	Date considered: <i>6-8-2002</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (modified)

Atty. Docket No.
GOUD:031USSerial No.
10/611,803

List of Patents and Publications for Applicant's

Applicant
Éric Gervais *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
July 1, 2003Group:
1615U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>JA</i>	C13	"Continuing need to prevent exposures during pregnancy to medications known to cause birth defects," <i>CDC Media Relations Press Release</i> , August 17, 2001.
	C14	Daniel <i>et al.</i> , "Interpretations of a teratogen warning symbol," <i>Teratology</i> , 64(3):148-153, 2001.
	C15	Pearson, "Proposed switch of Acyclovir from prescription to over-the-counter status," <i>National Women's Health Network</i> , May 19, 1994.
<i>JA</i>	C16	Pole <i>et al.</i> , "Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals," <i>J. Clin. Pharmacol.</i> , 40(6):573-577, 2000.

25441920.1

EXAMINER: *[Signature]*

DATE CONSIDERED: 6-8-2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.